Nurix competitors

John Gill works at Tetralogic Pharmaceuticals and a CEO at Tetralogic Pharmaceuticals and is based in Devon, Pennsylvania. He has worked as Director and Chief Operating Officer at 3-DIMENSIONAL PHARMACEUTICALS, INC.. John attended Rutgers University—Camden between 1973 and 1975 and Transylvania University between 1969 and 1971.

As a senior executive with 20+ years of sell- and buy- side business and corporate development experience, my career encompasses roles in therapeutics, biotech, genomics, medical devices, and pharmacy benefits. During my tenure at Pfizer, I completed more than 2 dozen acquisition, co-development, and licensing deals ranging from $300M to $7B. Later at Foundation Medicine, I led the $1B sale of their genomics testing to Roche, and earlier played a leadership role in Medco’s $29B sale to Express Scripts. I have worked extensively within R&D environments and launched 3 $1B+ therapeutic products in the hypertension and antibiotics categories. Additionally, I have been the CEO of early stage start-ups, building the funding, commercialization, and exit strategy for therapeutics companies in the CNS and autoimmune disease space.Currently, as CEO of Cognition Therapeutics, I am driving Series C fundraising effort. With multiple phase 2 clinical trials well under way for the Alzheimer’s research and more than a hundred million dollars in dedicated funding, I am repositioning the company to broaden the focus on our science and other CNS clinical conditions. I am pleased to lead a company dedicated to halting neurological disease processes and restoring and preserving the building blocks of brain health and function and look forward to sharing our progress here.

David L Lucchino works at ENTREGA INC and a Co-founder, President & Chief Executive Officer at FREQUENCY THERAPEUTICS, INC.; Trustee at Babson College; and Co-Founder at Semprus BioSciences and is based in Greater Boston Area. He has worked as Board Member at Semprus BioSciences, BOARD MEMBER at AdvaMed, and Account Supervisor at Dentsu. David works or has worked as Guest Lecturer at Harvard University, MEMBER at Sloan Fellows Program, and Guest Lecturer at University of Pennsylvania. He studied at Denison University between 1987 and 1991, Syracuse University between 1996 and 1997, and MIT Sloan between 2005 and 2006.

Mike has more than 20 years of experience in the biotechnology industry, with the last 14 focused on creating and operating early stage therapeutic-focused companies. He was most recently Chief Operating Officer at Decibel Therapeutics, a biotechnology company focused on broadly treating hearing disorders. Mike’s involvement at Decibel was part of his work as an Entrepreneur-in-Residence at Third Rock Ventures; he led a team that created Decibel’s business plan resulting in a $52 M Series A round. Prior to Decibel, Mike was Chief Operating Officer at Ember Therapeutics, a Third Rock Ventures company focused on obesity and diabetes, and Chief Business Officer at Link Medicine, a neurodegeneration focused biotechnology company that was sold to Astra Zeneca. Mike was also a founder and VP of Discovery at Epizyme Therapeutics, a company focused on epigenetic modulators that is now a publicly traded company, and VP of Discovery at Hypnion, Inc a sleep disorder company that was sold to Lilly in 2007 for $325 million. Mike also spent two years as a biotechnology analyst at Bank of America Securities. He started his career at Millennium Pharmaceuticals, where he was project leader for multiple programs.

John Fowler is a Managing Director at Montebello Holdings, Co-Founder and CEO at Kezar Life Sciences Inc, and Board Member at Kezar Life Sciences Inc and is based in South San Francisco, California. He has worked as Management Consultant at William Kent International, CEO at Aero Logistics, and Managing Director at Montebello Capital. John studied at Stanford Graduate School of Business between 1998 and 2000 and Stanford University between 1989 and 1993.

Dr. Worland has served as a member of the board of directors since February 2015. Dr. Worland is currently President and Chief Executive Officer and a director of eFFECTOR Therapeutics, Inc., a company focused on new treatments for cancer, where he has served since May 2012. Previously, Dr. Worland was President and Chief Executive Officer and a director of Anadys Pharmaceuticals, Inc., a biopharmaceutical company which discovered and developed treatments for hepatitis C and cancer, from August 2007 until the company’s acquisition by Roche in November 2011. Dr. Worland joined Anadys in 2001 and served in a number of executive roles prior to being named Chief Executive Officer, including President, Pharmaceuticals, and Chief Scientific Officer. Dr. Worland began his healthcare industry career at Agouron Pharmaceuticals, Inc. and remained with the company through its successful commercialization of an HIV protease inhibitor and successive acquisitions by Warner-Lambert and Pfizer. During this period, Dr. Worland held a number of positions, including Vice President, Antiviral Research and Director, Molecular Biology and Biochemistry. Dr. Worland was a National Institutes of Health Postdoctoral Fellow in Molecular Biology at Harvard University. Dr. Worland received his B.S. with highest honors in Biological Chemistry from the University of Michigan and his Ph.D. in Chemistry from the University of California, Berkeley.